Performance of an Autonomous Sanitary Sterilisation Ultraviolet Machine (ASSUM) on terminal disinfection of surgical theaters and rooms of an intensive-intermediate care unit.

(MDR) microorganisms UVC robot Ultraviolet- C (UV–C)

Journal

Infection prevention in practice
ISSN: 2590-0889
Titre abrégé: Infect Prev Pract
Pays: England
ID NLM: 101777928

Informations de publication

Date de publication:
Dec 2024
Historique:
received: 08 05 2024
accepted: 13 08 2024
medline: 23 9 2024
pubmed: 23 9 2024
entrez: 23 9 2024
Statut: epublish

Résumé

Ultraviolet- C (UV-C) light is effective for reducing environmental bioburden in hospitals, and the use of robots to deliver it may be advantageous. To evaluate the feasibility and clinical efficacy of an autonomous programmable UV-C robot in surgical and intensive care unit (ICU) rooms of a tertiary hospital. During ten consecutive months, the device was used in six theatres where cardiac, colorectal and orthopaedic surgeries were performed, and in the rooms previously occupied by patients subjected to contact precautions of a 14-bed ICU. Surgical site infection (SSI) rates of procedures performed in the UV-cleaned theatres were compared with those of the previous year. Incidence in clinical samples of ICU-acquired multiple-drug resistant (MDR) microorganisms was compared with that of the same period of the previous year. An UV-C exposure study done by semi-quantitative dosimeters and a survey of the bioburden on surfaces were carried out. SSI rates in the pre- and post-intervention periods were 8.67% (80/922) and 7.5% (61/813), respectively (p=0.37). Incidence of target microorganisms in clinical samples remained unchanged (38.4 vs. 39.4 per 10,000 patient-days, p=0.94). All the dosimeters exposed to ≤1 meter received ≥500 mJ/cm Deployment of an UV-C robot in surgical and ICU rooms is feasible, ensures adequate delivery of germicidal UV-C light and reduces the environmental bacterial burden. Rates of surgical site infections or acquisition of MDR in clinical samples of critically-ill patients remained unchanged.

Sections du résumé

Background UNASSIGNED
Ultraviolet- C (UV-C) light is effective for reducing environmental bioburden in hospitals, and the use of robots to deliver it may be advantageous.
Aim UNASSIGNED
To evaluate the feasibility and clinical efficacy of an autonomous programmable UV-C robot in surgical and intensive care unit (ICU) rooms of a tertiary hospital.
Method UNASSIGNED
During ten consecutive months, the device was used in six theatres where cardiac, colorectal and orthopaedic surgeries were performed, and in the rooms previously occupied by patients subjected to contact precautions of a 14-bed ICU. Surgical site infection (SSI) rates of procedures performed in the UV-cleaned theatres were compared with those of the previous year. Incidence in clinical samples of ICU-acquired multiple-drug resistant (MDR) microorganisms was compared with that of the same period of the previous year. An UV-C exposure study done by semi-quantitative dosimeters and a survey of the bioburden on surfaces were carried out.
Findings UNASSIGNED
SSI rates in the pre- and post-intervention periods were 8.67% (80/922) and 7.5% (61/813), respectively (p=0.37). Incidence of target microorganisms in clinical samples remained unchanged (38.4 vs. 39.4 per 10,000 patient-days, p=0.94). All the dosimeters exposed to ≤1 meter received ≥500 mJ/cm
Conclusion UNASSIGNED
Deployment of an UV-C robot in surgical and ICU rooms is feasible, ensures adequate delivery of germicidal UV-C light and reduces the environmental bacterial burden. Rates of surgical site infections or acquisition of MDR in clinical samples of critically-ill patients remained unchanged.

Identifiants

pubmed: 39308772
doi: 10.1016/j.infpip.2024.100396
pii: S2590-0889(24)00060-X
pmc: PMC11415570
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100396

Informations de copyright

© 2024 The Authors.

Auteurs

Sabina Herrera (S)

Infectious Disease Service, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain.
CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.

Ignasi Roca (I)

Department of Microbiology, Biomedical Diagnostic Center (CDB) and ISGlobal, Hospital Clínic, University of Barcelona, Barcelona, Spain.
CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.

Ana Del Río (A)

Infectious Disease Service, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain.
CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.

Javier Fernández (J)

Liver ICU, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS and CIBERehd, Spain.
EF Clif, EASL-CLIF Consortium, Barcelona, Spain.
CovidWarriors, Barcelona, Spain.

Cristina Pitart (C)

Department of Microbiology, Biomedical Diagnostic Center (CDB) and ISGlobal, Hospital Clínic, University of Barcelona, Barcelona, Spain.
CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.

Isabel Fortes (I)

Preventive Medicine Service, Hospital Clinic, University of Barcelona, IDIBAPS, Barcelona, Spain.

Blanca Torralbo (B)

Preventive Medicine Service, Hospital Clinic, University of Barcelona, IDIBAPS, Barcelona, Spain.

Gemina Santana (G)

Preventive Medicine Service, Hospital Clinic, University of Barcelona, IDIBAPS, Barcelona, Spain.

Romina Parejo-González (R)

Preventive Medicine Service, Hospital Clinic, University of Barcelona, IDIBAPS, Barcelona, Spain.

Andreu Veà-Baró (A)

Andreu Veà, Ph.D. advisor to the CEO (on Digital-Transformation & Optimization) Hospital Clinic Barcelona CovidWarrior, Barcelona, Spain.

Josep Maria Campistol (JM)

Hospital Clínic, University of Barcelona, August Pi i Sunyer Biomedical Research Institute Barcelona, Spain.

Mireia Aguilar (M)

Department of Microbiology, Biomedical Diagnostic Center (CDB) and ISGlobal, Hospital Clínic, University of Barcelona, Barcelona, Spain.
CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.

Sergi Degea (S)

Department of Microbiology, Biomedical Diagnostic Center (CDB) and ISGlobal, Hospital Clínic, University of Barcelona, Barcelona, Spain.
CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.

Climent Casals-Pascual (C)

Department of Microbiology, Biomedical Diagnostic Center (CDB) and ISGlobal, Hospital Clínic, University of Barcelona, Barcelona, Spain.
CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.

Alex Soriano (A)

Infectious Disease Service, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain.
CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.

José A Martínez (JA)

Infectious Disease Service, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain.
CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.

Classifications MeSH